Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001038

Drug Information
NameExenatide
SynonymsUNII-9P1872D4OL; 335149-21-8; LY2148568; L-Serinamide, L-histidylglycyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alpha-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-alpha-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-; Exenatide Synthetic; Exendin-4; AC 2993A; Exenatide; Extendin-4; 141732-76-5; Exendin 4; 286014-72-0; C074031; AC 2993 LAR; Exendin 4 (Heloderma suspectum); 141758-74-9; Byetta; CHEMBL414357; Ex4 peptide; CHEBI:490990; Exendin 3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-; AC 2993
Trade NameByetta
CompanyEli Lilly and Company
IndicationDiabetes mellitus
[ICD9: 250   ICD10: E08-E13]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)
258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168
(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)21
9-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63
-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(
266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294
)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-12
4(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-
166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)21
2-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(
251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-1
43(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133
(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)2
24-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(2
84)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36
-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153
(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-
102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-14
9,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)
(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,2
65)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,
276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211
,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,21
7,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,2
23,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,
229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H
,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,10
6-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,11
9-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,13
2-,146-,147-,148-,149-/m0/s1
InChIKeyHTQBXNHDCUEHJF-XWLPCZSASA-N
Canonical SMILESCCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)
NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC
(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=
O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)
C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C
(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C
(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC
(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CN=CN9)N    
Isomeric SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C
(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)
NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)
C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)
NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=
O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC
(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]
(CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]
(CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H]
(C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CN=CN9)N
Therapeutic ClassHypoglycemic Agents
CAS NumberCAS 141758-74-9
FormulaC184H282N50O60S
PubChem Compound IDCID 16157882.
PubChem Substance IDSID 3814631.
SuperDrug ATC IDA10BX04
A10BX04
TargetGlucagon-like peptide 1 receptorBinder[2]
Ref 1Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. To Reference
Ref 2Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol Ther. 2009 Jun;11(6):353-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543